Literature DB >> 15019164

Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II.

Per Lund1, Dominic Schubert, Fataneh Niketeghad, Peter Schirmacher.   

Abstract

Insulin-like Growth Factor (IGF)-II is frequently overexpressed in experimental and human hepatocellular carcinomas (HCCs) and has been correlated with increased tumor growth. We have analyzed, whether IGF-II affects chemotherapy response and apoptosis in human liver tumor cells. Three liver tumor cell lines highly expressed IGF-II and supported their growth in an autocrine manner by secreting excessive amounts of IGF-II. Neutralization of IGF-II significantly increased response to the chemotherapeutic agents cisplatin and etoposide especially at lower, cytostatic doses. While blocking of IGF-II did not increase spontaneous cell death in exponentially growing cultures, increased cell death was found under conditions of confluent growth and chemotherapy. Thus in HCC cells, IGF-II is a relevant protumorigenic growth factor that significantly reduces susceptibility to apoptosis and chemotherapeutic treatment. Therefore interference with IGF-II activity may improve response of HCCs to otherwise inefficient chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019164     DOI: 10.1016/j.canlet.2003.10.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  [Molecular mechanisms of progression in human hepatocarcinogenesis].

Authors:  K Breuhahn
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Epigenetic modulation of insulin-like growth factor-II overexpression by hepatitis B virus X protein in hepatocellular carcinoma.

Authors:  Xu You Liu; Shao Hui Tang; Sheng Lan Wu; Yu Hong Luo; Ming Rong Cao; Hong Ke Zhou; Xiang Wu Jiang; Jian Chang Shu; Cai Qun Bie; Si Min Huang; Zhan Hong Zheng; Fei Gao
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 3.  Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?

Authors:  Alex Boye; Yu-Hong Zou; Yan Yang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma.

Authors:  Evan J Walker; Stephen A Rosenberg; Jack R Wands; Miran Kim
Journal:  For Immunopathol Dis Therap       Date:  2011

Review 5.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

6.  Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma.

Authors:  Minoru Tomizawa; Hiromitsu Saisho
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

7.  Multiple roles and therapeutic implications of Akt signaling in cancer.

Authors:  Emiliano Calvo; Victoria Bolós; Enrique Grande
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 8.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 9.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells.

Authors:  Ya-Wen Chen; Victor Boyartchuk; Brian C Lewis
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.